Report From the 51st American Society of Hematology Annual Meeting and Exposition: Malignant Hematology

The latest reports on treatment of B-cell lymphomas and high- and low-risk Hodgkin lymphomas

Nearly 30 sessions covering diverse aspects of hematology were presented at the 51st meeting of the American Society of Hematology (ASH) in New Orleans from December 5 through December 8, 2009 (ASH 2009). Two editors from Journal Watch Oncology and Hematology attended the conference and reported some of the highlights. In this first installment, Michael E. Williams, MD, discusses the latest research in malignant hematology.

A New Front-Line Regimen for B-Cell Lymphoma?

Bendamustine — an alkylating agent with novel mechanisms of action — produces high response rates and has a favorable toxicity profile when used with rituximab in relapsed B-cell non-Hodgkin lymphomas (NHLs; J Clin Oncol 2005; 23:3383 and J Clin Oncol 2008; 26:4473). To explore…

Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee